LMNL

Liminal BioSciences Inc. [LMNL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LMNL Stock Summary

Top 10 Correlated ETFs

LMNL


Top 10 Correlated Stocks

LMNL


In the News

04:08 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.

04:38 26 Mar 2023 LMNL

Liminal BioSciences to Present at BIO CEO & Investor Conference

LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.

10:17 26 Mar 2023 LMNL

Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript

Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.

03:22 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.

08:30 26 Mar 2023 LMNL

Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).

06:52 26 Mar 2023 LMNL

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia.  The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.

04:54 26 Mar 2023 LMNL

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

04:10 26 Mar 2023 LMNL

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million.

08:46 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript

09:19 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LMNL Financial details

Company Rating
Strong Buy
Market Cap
12.05M
Income
500K
Revenue
401K
Book val./share
1.3
Cash/share
1.31
Dividend
-
Dividend %
-
Employees
251
Optionable
No
Shortable
Yes
Earnings
08 May 2023
P/E
-10.38
Forward P/E
-
PEG
1.08
P/S
302.87
P/B
2.98
P/C
2.96
P/FCF
-0.31
Quick Ratio
4.63
Current Ratio
4.85
Debt / Equity
0.33
LT Debt / Equity
0.02
-
-
EPS (TTM)
0.02
EPS next Y
-
EPS next Q
-0.5
EPS this Y
274.65%
EPS next Y
-
EPS next 5Y
-81929.35%
EPS last 5Y
NAN%
Revenue last 5Y
-61.49%
Revenue Q/Q
7933.33%
EPS Q/Q
-122.26%
-
-
-
-
SMA20
-23.72%
SMA50
19.77%
SMA100
-20.83%
Inst Own
0.59%
Inst Trans
-0.06%
ROA
-22%
ROE
-32%
ROC
-0.8%
Gross Margin
-
Oper. Margin
-8976%
Profit Margin
-2917%
Payout
-
Shs Outstand
3.1M
Shs Float
1.11M
-
-
-
-
Target Price
-
52W Range
3.1-10.9
52W High
-61.17%
52W Low
+29.44%
RSI
25.73
Rel Volume
0.14
Avg Volume
8.46K
Volume
1.21K
Perf Week
-14.09%
Perf Month
-29.65%
Perf Quarter
-7.55%
Perf Half Y
-13.98%
-
-
-
-
Beta
30.7745
-
-
Volatility
0.16%, 0.67%
Prev Close
1.92%
Price
3.8831
Change
1.92%

LMNL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
57.1966.150.310.140.02
Net income per share
-160.44-272.78-12.81-4.830.43
Operating cash flow per share
-179.21-115.13-6.19-3.11-3.3
Free cash flow per share
-193.95-122.29-6.46-3.19-3.32
Cash per share
33.8710.323.821.843.6
Book value per share
178.35-79.036.360.951.41
Tangible book value per share
-19.32-115.825.05-0.021.01
Share holders equity per share
178.35-79.036.360.951.41
Interest debt per share
147.19217.633.813.382.22
Market cap
8.91B1.9B1.76B1.31B419.02M
Enterprise value
8.98B2.03B1.74B1.34B371.31M
P/E ratio
-81.18-9.74-8.55-11.132.53
Price to sales ratio
227.7440.16358.47394.55651.66
POCF ratio
-72.67-23.07-17.69-17.24-4.21
PFCF ratio
-67.15-21.72-16.93-16.79-4.19
P/B Ratio
73.02-33.6117.256.669.83
PTB ratio
73.02-33.6117.256.669.83
EV to sales
229.5142.82355.57403.27577.47
Enterprise value over EBITDA
-80.42-10.82-9.58-13.2515.68
EV to operating cash flow
-73.24-24.6-17.54-17.62-3.73
EV to free cash flow
-67.67-23.16-16.79-17.16-3.71
Earnings yield
-0.01-0.1-0.12-0.090.03
Free cash flow yield
-0.01-0.05-0.06-0.06-0.24
Debt to equity
1.15-2.930.694.452.16
Debt to assets
0.491.610.420.870.73
Net debt to EBITDA
-0.62-0.670.08-0.29-2.02
Current ratio
2.011.143.033.076.2
Interest coverage
-14.9-5.09-8.41-10.79-7.84
Income quality
1.120.420.480.64-7.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
2.571.9315.3217.1328.53
Intangibles to total assets
0.550.190.080.130.03
Capex to operating cash flow
0.080.060.040.030
Capex to revenue
-0.26-0.11-0.91-0.62-0.72
Capex to depreciation
-2.2-0.94-0.45-0.24-0.11
Stock based compensation to revenue
0.220.144.411.876.58
Graham number
802.38696.4742.8210.133.69
ROIC
-0.5-1.57-3.69-5.080.51
Return on tangible assets
-0.86-2.35-1.36-1.150.11
Graham Net
-133.13-192.20.3-2.050.57
Working capital
36.26M5.11M63.59M49.24M96.14M
Tangible asset value
-13.22M-82.95M81.09M-480K30.37M
Net current asset value
-68.17M-125.2M24.69M-29.75M22.46M
Invested capital
0.76-2.360.463.21.43
Average receivables
9.87M15.46M16.64M8.6M2.49M
Average payables
16.8M20.22M15.8M9.82M7.46M
Average inventory
24.84M24.02M9.78M8.45M4.69M
Days sales outstanding
102.23153.88989.91429.48606.25
Days payables outstanding
695.29202.631.39K1.64K0
Days of inventory on hand
1.3K115.539951.68K0
Receivables turnover
3.572.370.370.850.6
Payables turnover
0.521.80.260.220
Inventory turnover
0.283.160.370.220
ROE
-0.93.45-2.01-5.110.3
Capex per share
-14.74-7.16-0.28-0.08-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.01000.010
Net income per share
2.74-0.21-0.34-0.190.71
Operating cash flow per share
-1.91-0.16-0.23-0.22-0.38
Free cash flow per share
-1.91-0.16-0.23-0.22-0.38
Cash per share
3.91.351.971.81.31
Book value per share
1.880.531.050.881.3
Tangible book value per share
1.460.380.750.571.3
Share holders equity per share
1.880.531.050.881.3
Interest debt per share
2.170.780.780.770.08
Market cap
871.74M1.12B384.24M203.41M178.29M
Enterprise value
818.21M1.07B345.79M170.72M139.1M
P/E ratio
2.65-16.43-9.06-8.572.03
Price to sales ratio
5.13K4.69K01.3K59.43K
POCF ratio
-15.25-87.27-54.54-30.01-15.24
PFCF ratio
-15.22-87.22-54.54-29.97-15.24
P/B Ratio
15.4626.1811.767.464.41
PTB ratio
15.4626.1811.767.464.41
EV to sales
4.81K4.49K01.09K46.37K
Enterprise value over EBITDA
9.64-73.76-37.42-35.626.01
EV to operating cash flow
-14.31-83.54-49.08-25.19-11.89
EV to free cash flow
-14.28-83.49-49.08-25.16-11.89
Earnings yield
0.09-0.02-0.03-0.030.12
Free cash flow yield
-0.07-0.01-0.02-0.03-0.07
Debt to equity
1.772.161.651.950.33
Debt to assets
0.680.730.70.750.25
Net debt to EBITDA
-0.633.294.166.82-1.69
Current ratio
6.216.22.772.354.85
Interest coverage
-7.58-6.24-6.82-9.71-8.26
Income quality
-0.70.750.661.14-0.53
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00029.61.46K
Research and developement to revenue
29.2519.07025.111.17K
Intangibles to total assets
0.030.03000.06
Capex to operating cash flow
00000
Capex to revenue
-0.76-0.030-0.05-1
Capex to depreciation
-0.16-0.010-0.03-0.01
Stock based compensation to revenue
10.372.6203.42137.67
Graham number
10.781.592.841.944.55
ROIC
0.170.110.170.210.29
Return on tangible assets
0.57-0.14-0.14-0.080.43
Graham Net
0.60.210.260.120.91
Working capital
113.33M96.14M42.69M35M35.18M
Tangible asset value
43.63M30.37M23.35M17.65M37.1M
Net current asset value
35.35M22.46M12.97M7.77M30.82M
Invested capital
1.121.430.70.850.04
Average receivables
1.43M1.14M933.5K1.14M1.49M
Average payables
02.88M6.93M4.05M0
Average inventory
00000
Days sales outstanding
639.53403.870848.4144.94K
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.140.2200.110
Payables turnover
00000
Inventory turnover
00000
ROE
1.46-0.4-0.32-0.220.54
Capex per share
00000

LMNL Frequently Asked Questions

What is Liminal BioSciences Inc. stock symbol ?

Liminal BioSciences Inc. is a CA stock , located in Laval of Qc and trading under the symbol LMNL

What is Liminal BioSciences Inc. stock quote today ?

Liminal BioSciences Inc. stock price is $3.8831 today.

Is Liminal BioSciences Inc. stock public?

Yes, Liminal BioSciences Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap